logo
In Their Final Moments, a Pompeii Family Fought to Survive

In Their Final Moments, a Pompeii Family Fought to Survive

New York Times11-05-2025

One day in the year 79, Pompeii came under fire. The explosion of nearby Mount Vesuvius sent a mushroom cloud of ash and rock into the atmosphere, pummeling the ancient Roman trading hub and resort in a ceaseless hail of tiny volcanic rocks.
Many residents ran for their lives, trying to find safety with their loved ones before searing volcanic debris buried the estimated 1,500 residents who remained in Pompeii.
In a study published last month in the journal Scavi di Pompei, scientists documented events at one home in the doomed city where a family sought refuge inside a back room by pushing a wooden bed against a door in a vain attempt to stop a flood of volcanic rocks from the sky, known as lapilli.
The small-but-well-appointed residence is known as the House of Helle and Phrixus, after a richly decorated fresco in the dining room. It depicts the mythological siblings Phrixus and Helle escaping their wicked stepmother on a winged ram only to have Helle fall and, ominously, drown in the sea below.
As with many ancient Roman residences, its atrium, an open-roof room centrally located in the home, was used for ventilation and rainwater collection. But on that day, the recess allowed volcanic rock to more rapidly overtake the space. Most Pompeians 'had no clue what was happening,' said Gabriel Zuchtriegel, an author of the study and the director of the Archaeological Park of Pompeii. 'Many thought the end of the world had come,' he added.
In the years that followed, the hot ash that eventually buried the home solidified and left an imprint that archaeologists filled with plaster to reconstruct the shape of the wooden bed that remained. The technique helps illustrate the horror of the Pompeian dead in their final moments and how perishable everyday items made of wood, textiles and leather were situated in their environments.
The skeletal remains of four people, most likely members of the same family, were identified in the study. The lapilli, which reached heights as high as nine feet in some locations, could not be controlled, and researchers believe the people made a final attempt to escape, leaving the small room in which they had barricaded themselves. They got only as far as the triclinium, the formal dining room where their remains were found.
'The family in the House of Helle and Phrixus probably died when the so-called pyroclastic flow, an avalanche of hot ash and toxic gas, arrived and parts of the building collapsed,' Dr. Zuchtriegel said.
He and his colleagues suggest that the remains of the four people found in the home were from a family that stayed behind and may have included some enslaved members who worked at the residence. Still, archaeologists don't know for sure if they lived there or simply took refuge after the homeowners had already escaped.
'It's not certain that the individuals found in the house as victims were part of the family,' said Marcello Mogetta, an associate professor of Roman art and archaeology at the University of Missouri who was not involved in the study.
Among the skeletal remains was a bronze bulla that belonged to a child. The ancient amulets were worn like lockets around the necks of young free boys to shield them from danger until they reached adulthood.
'The amulet was supposed to protect them, so there's a cruel irony to the fact that it didn't,' said Caitie Barrett, a professor of archaeology at Cornell University who was not involved in the study.
Bourbon explorers sent by Charles III in the 18th century carried out rudimentary excavations of Pompeii that disturbed the skeletal remains of the victims found in the House of Helle and Phrixus. When they tunneled into the residence in search of valuables like jewelry and artwork, they left behind holes in the walls. These early excavators often had little interest in human remains, either in respecting their preservation, dignifying their deaths or studying their material culture.
But today it's the human toll that feels most prominent for archaeologists and for many of the visitors who regularly pour into Pompeii. Whether or not the remains belonged to those who were indeed family will be something that researchers may try to uncover through DNA analysis in the near future.
Family or not, it doesn't change the human tragedy of the story.
'Whatever the nature of their specific relations, they would have been the last people to offer each other comfort at the end,' Dr. Barrett said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dead Sea Scrolls could be even older than previously thought, according to new study
Dead Sea Scrolls could be even older than previously thought, according to new study

Fox News

timea day ago

  • Fox News

Dead Sea Scrolls could be even older than previously thought, according to new study

Print Close By Andrea Margolis Published June 05, 2025 The Dead Sea Scrolls may be even older than researchers thought, according to a new study driven by an artificial intelligence (AI) model. A group of researchers from the Netherlands, Italy and Denmark recently published their findings in the journal PLOS One on June 4. The researchers said they developed an AI-based date-prediction model named Enoch, a nod to the biblical patriarch of the same name. ANCIENT CHRISTIAN FIGURINES DISCOVERED IN 1,500-YEAR-OLD DESERT GRAVES Enoch "was trained as a machine learning-based date-prediction model applying Bayesian ridge regression on established handwriting-style descriptors," according to the study. In order to date the scrolls, the model analyzed each one's handwriting style. Researchers also integrated radiocarbon dating methods — and found that most of the scrolls were at least a generation older than previously thought. Previous estimates placed the scrolls between 150 and 50 B.C., but the model found that many of the scrolls date to around 200 B.C. "There are no compelling paleographic or historical reasons that preclude these older dates as reliable time markers." "Enoch's style-based predictions are often older than traditionally assumed paleographic estimates, leading to a new chronology of the scrolls and the re-dating of ancient Jewish key texts that contribute to current debates on Jewish and Christian origins," the paper states. LITTLE GIRL DISCOVERS 3,800-YEAR-OLD AMULET WITH TIES TO BIBLICAL PEOPLE DURING FAMILY TRIP The researchers also indicate that the new dates are "realistic." "There are no compelling paleographic or historical reasons that preclude these older dates as reliable time markers," the authors said. For more Lifestyle articles, visit The scrolls, found in desert caves near the Dead Sea in the 1940s and 1950s, date between the third century B.C. to the first century A.D. They offer a wealth of knowledge about ancient Judaism, with many religious texts during the Second Temple period that were previously unknown. CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER Since their discovery, the scrolls have attracted a great amount of interest from both scholars and the public at large. In 2021, Israeli researchers uncovered dozens of new Dead Sea Scroll fragments. CLICK HERE TO GET THE FOX NEWS APP In April, the Ronald Reagan Presidential Library showcased a special collection of eight ancient Jewish manuscripts as part of its exhibition on the Dead Sea Scrolls. Print Close URL

Earthquake damages part of Pompeii site in southern Italy
Earthquake damages part of Pompeii site in southern Italy

Yahoo

time2 days ago

  • Yahoo

Earthquake damages part of Pompeii site in southern Italy

ROME (Reuters) -A minor earthquake in southern Italy has caused the partial collapse of a wall and a portion of a vault at the Pompeii archaeological site, authorities said on Thursday. The quake with a magnitude of 3.2 on Thursday morning was the latest in a series of tremors centred on the nearby Campi Flegrei super volcano close to the city of Naples. The affected area of Pompeii had been damaged in a major earthquake that hit southern Italy in 1980 and had since been shored up and restored. There were no frescoes or movable relics in the damaged structure and no one was injured. Gabriel Zuchtriegel, the site's director, said checks were being carried out to ensure no other areas had been affected. The ancient settlement of Pompeii was destroyed by the eruption of Mount Vesuvius in 79 AD. (Writing by Keith Weir, editing by Giselda Vagnoni)

Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC
Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC

Medscape

time2 days ago

  • Medscape

Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC

The latest results from the BREAKWATER trial have confirmed encorafenib plus cetuximab with chemotherapy as the new first-line standard of care for BRAF V600E-mutant metastatic colorectal cancer (CRC), according to research presented at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. At the interim analysis, encorafenib plus cetuximab with mFOLFOX6 chemotherapy doubled median overall survival compared with the current standard of care — investigators' choice of chemotherapy with or without bevacizumab. In addition, at a median follow-up of 16.8 months, the new treatment regimen led to a significant improvement in median progression-free survival of almost 6 months. This survival finding is 'unprecedented' and 'practice changing' for these patients who historically have a poor prognosis, said lead investigator and presenter Elena Élez, MD, PhD, a gastrointestinal medical oncologist at the Vall d'Hebron University Hospital in Barcelona, Italy. The study was published in The New England Journal of Medicine to coincide with Élez's presentation. BRAF mutations, which occur in up to 12% of patients with metastatic CRC, are associated with poor outcomes. In December 2024, the US Food and Drug Administration (FDA) granted accelerated approval for the BRAF inhibitor encorafenib alongside cetuximab and mFOLFOX6 for patients with metastatic CRC and a BRAF V600E mutation. This approval was based on earlier results from BREAKWATER that showed a 21% higher objective response rate and a longer duration of response with this regimen. The accelerated approval means that this regimen has already been making its way into the clinic, but 'we were all waiting for this [latest] data,' Pamela Kunz, MD, chief of Gastrointestinal Medical Oncology at Yale University in New Haven, Connecticut, told Medscape Medical News . The doubling of overall survival 'is a big deal,' she said. In the trial, patients were randomly assigned to receive either first-line encorafenib plus cetuximab with mFOLFOX6 (n = 236) or to a control group — physician's choice of either mFOLFOX6, FOLFOXIRI, or CAPOX chemotherapy (n = 243). Most patients in the control arm also received the tumor angiogenesis inhibitor bevacizumab. The broad options in the control arm speak to how heterogeneous treatment has been for BRAF V600E-mutant metastatic CRC, said study discussant Andrea Sartore-Bianchi, MD, a medical oncologist at the University of Milan, Milan, Italy. Patients in the trial had received no prior systemic therapy for metastatic disease. Investigators excluded patients with high levels of microsatellite instability because they are candidates for immunotherapy. At a median follow-up of 16.8 months, median progression-free survival was 12.8 months for the encorafenib group compared with 7.1 months for the control group (hazard ratio [HR], 0.53; P < .0001). At a median follow-up of 22 months, overall survival was 30 months in the encorafenib group compared with 15 months in the control group (HR, 0.49; P < .0001). The benefits of the combination were held up in high-risk subgroups, including in patients with liver metastases and those with metastases in three or more organs. With the use of more agents and a longer duration of treatment due to improved efficacy, there was an expected increase in toxicity with the new regimen. The rate of treatment-related grade 3/4 adverse events was 76.3% with encorafenib vs 58.5% with the control regimen. Patients receiving encorafenib also had higher rates of anemia, arthralgia, rash, and pyrexia, but there was no substantial increase in treatment discontinuation. BREAKWATER also included an encorafenib plus cetuximab arm without chemotherapy, but enrollment was stopped early at 158 patients due to possible futility. Still, these patients had as good or numerically better outcomes than the control group, which means the drug combination alone is a valid option for those unable to tolerate chemotherapy, said Élez. 'The results are striking,' said Sartore-Bianchi in his discussion. 'Now that we have the big picture' from BREAKWATER, the combination should be considered the first-line standard of care. Mark A. Lewis, MD, a gastrointestinal medical oncologist at Intermountain Healthcare in Murray, Utah, explained that what usually happens in metastatic CRC is that people are treated with chemotherapy for a bit before oncologists notice the tumor is behaving more aggressively than expected and order a BRAF test. This delay is now 'completely unacceptable,' he told Medscape Medical News . The takeaway from BREAKWATER is that testing must come sooner. To help with BRAF testing, the FDA approved the Qiagen therascreen BRAF V600E RGQ polymerase chain reaction kit. 'As soon as you know patients are BRAF -mutated, you need to play your entire hand' because it will double survival,' said Lewis. 'This absolutely validates a biomarker-informed approach to colon cancer,' similar to what we have in breast cancer. BREAKWATER was funded primarily by Pfizer, maker of encorafenib, with support from Eli Lilly and Merck, who jointly market cetuximab. Élez reported numerous ties to the companies, including research grants, travel funding, honoraria, and/or consultant work. Lewis, Kunz, and Sartore-Bianchi had no relationships with the firms.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store